Non-antivitamin oral anticoagulants K (AONV, also known as NACOs or ADOs) are the next-generation anticoagulants. There are 3 of them: apixaban (Eliquis®), rivaroxaban (Xarelto®) and dabigatran (Pradaxa®). They have the advantage of not requiring medical surveillance by INR unlit Vitamins K. An advantage ... but it is also a drawback, because one might fear a poor efficacy of these new drugs, or the occurrence of effects serious side effects. The first studies on the use of these new treatments are however reassuring. It should be noted that a follow-up blood test is currently being developed.
However, these drugs have the disadvantage of not having antidotes in case of overdose (the pharmaceutical industry is working to develop one).
An alternative to AVK
These new oral anti-vitamin K anticoagulants should not be prescribed as first-line therapy (vitamin K antagonists are usually given). And if they are poorly tolerated, if they are contraindicated, or if the INR fails to be at values between 2 and 3, then the doctor may consider oral anticoagulants not antivitamin K. In short, as the High Authority of Health indicates in its 2013 opinion, these new drugs should be considered as an alternative to vitamin K antagonists.